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Abstract: Allergic rhinitis (AR) is a high prevalence disease, affecting 10%–20% of the   general 
population. AR is sustained by an IgE-mediated reaction, and by a complex inflammatory   network 
of cells, mediators, and cytokines, becoming chronic when exposure to allergen persists. A 
Th2-biased immune response is the basis for the allergic inflammation. Histamine plays a rel-
evant role in symptom occurrence. Therefore, antihistamine use represents a   cornerstone in AR 
management. Ebastine, a novel antihistamine, is effective overall in controlling symptoms, and 
its safety profile is good. Recently, a new formulation has been developed, ie, a fast-  dissolving 
tablet. Several studies have demonstrated its favorable characteristics. In conclusion, ebastine 
is an effective and well tolerated antihistamine that may be prescribed for the treatment of 
AR. The fast-dissolving tablet formulation provides a new option which may be particularly 
convenient for the patient.
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Introduction
Allergic rhinitis (AR) is the most common immune-mediated disease. AR is defined 
as a symptomatic disease of the nasal mucosa following an IgE-mediated reaction.1 
Numerous questionnaire-based surveys performed in the last decade report that the 
prevalence ranges between 10% and 20% (widely variable between different countries) 
and can be as high as 25% in adolescents.2–4 Although AR is not a life-threatening 
condition, it has been documented to have a significant impact on quality of life and 
is associated with significant costs.5–7 Moreover, AR is often associated with asthma, 
and is a risk factor for asthma onset and worsening.1 Thus, optimal treatment of AR 
would lead to improved quality of life, reduced occurrence of comorbidities, and better 
control of asthma, with relevant socioeconomic implications. Presently, there are a 
number of effective therapeutic pharmacologic options available, but the general belief 
is that treatment can be improved upon by ameliorating patient adherence, the safety 
profile of existing drugs, or modifying the immune response in the early stages.
From a pathophysiologic point of view, AR is characterized essentially by an 
inflammatory process (allergic inflammation) that starts with IgE-dependent mast cell 
degranulation. Histamine is the main mediator of the early phase, and is responsible 
for the typical symptoms of sneezing, itching, rhinorrhea, and nasal obstruction.8 Upon 
activation, mast cells trigger synthesis of other inflammatory mediators, including 
  leukotrienes and prostaglandins, and secretion of cytokines. Thus, the immediate 
phase is followed by delayed infiltration of the nasal mucosa by leukocytes, mainly Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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eosinophils,9 that are considered the hallmark of allergic 
inflammation.10 The selective accumulation of inflamma-
tory cells at the nasal level is orchestrated by the adhesion 
machinery. Obviously, the recruited inflammatory cells are 
also important sources of mediators and cytokines that main-
tain, amplify, and enhance allergic inflammation.
T-cells are pivotal in the inflammation associated with 
allergy, but also are responsible of the development of 
the so-called allergic phenotype. In fact, allergic subjects 
have an imbalance between the two subsets of TCD4+, 
ie, Th1 and Th2, in favor of the Th2 phenotype. Indeed, 
Th1 cells are responsible for the usual host defense against 
  bacterial and viral pathogens, whereas Th2 cells produce the 
  cytokines, ie, interleukin (IL)-3, IL-4, IL-5, and IL-13, that 
are involved in IgE synthesis and in eosinophil and fibroblast 
activation.11,12 The balance between Th1 and Th2 cells is 
regulated by so-called regulatory cells. A defect in the activity 
of these regulatory cells can lead either to allergy or to auto-
immune disease.13,14 Finally, it has been documented that a 
weak inflammatory infiltrate may be present in the nose, even 
in absence of symptoms, when a subthreshold exposure to the 
allergen persists (minimal persistent inflammation).15 Thus, 
the duration of exposure to allergen, rather than the type of 
allergen, is critical for allergic inflammation. For this reason, 
a new classification of AR has been recently proposed and 
validated, so the traditional terms “seasonal” and “perennial” 
have been replaced by “intermittent” and “persistent”. Also, 
based on symptom impact on daily life, the severity has been 
graded as mild or moderate/severe. The treatment of AR has 
four components, ie, patient education, allergen avoidance, 
drug therapy, and specific immunotherapy.
Allergen avoidance
Unfortunately, meta-analyses of the studies dealing with 
allergen avoidance/control measures report only a marginal 
and inconsistent benefit.16 Indeed, it is clear that the avail-
able environmental interventions (high-efficiency particulate 
air filters, acaricides, impermeable bed covers, etc) are not 
sufficient if used alone to treat symptoms. Moreover, with 
  outdoor allergens, such as pollens or molds, there is no 
feasible intervention. Nonetheless, reasonable avoidance 
measures are always recommended for allergic patients.
Pharmacotherapy
Drugs are prescribed according to the ARIA (Allergic 
Rhinitis and its Impact on Asthma) guidelines on the basis 
of frequency and severity of symptoms, in a stepwise manner 
(as made for asthma). Oral and topical second-generation H1 
antihistamines (azelastine, cetirizine, desloratadine, ebastine, 
fexofenadine, levocabastine, levocetirizine, loratadine) are 
recommended in all steps of the disease due to their good 
risk:benefit ratio and the additional anti-inflammatory 
  activities exerted by some molecules.17 Moreover, it has been 
suggested that long-term use of antihistamines is preferable 
to symptomatic therapy.18
Nasal glucocorticosteroids (beclomethasone, budesonide, 
ciclesonide, flunisolide, fluticasone, mometasone, triamci-
nolone) are the most efficacious medications available for 
the treatment of AR. Due to their broad anti-inflammatory 
action, they also control nasal obstruction well. Intranasal 
corticosteroids are generally well tolerated, despite some 
concerns about possible side effects. Therefore, caution 
is recommended when using long-term treatments, and 
especially when nasal steroids are used in association with 
inhaled steroids.19 Decongestants or vasoconstrictors have 
a rapid action on nasal congestion, but their long-term use 
is associated with atrophy of the nasal mucosa (rhinitis 
medicamentosa). Decongestants are indicated only for short 
courses of treatment, in association with other drugs. Other 
possible treatments include cromones, leukotriene modifiers 
(especially when asthma coexists), anticholinergics, and 
nasal lavage.
Allergen-specific immunotherapy
Allergen-specific immunotherapy (SIT) is the procedure 
of administering increasing amounts of the allergen(s) in 
order to achieve hyposensitization (ie, tolerance to the causal 
allergen), and thereby reduce symptoms (and need for relief 
medications) when exposure to the allergen occurs. Since its 
empiric introduction in 1911, SIT was administered by sub-
cutaneous injection. This practice has been demonstrated to 
carry some risk for fatal or near-fatal adverse events, includ-
ing asthma, angioedema, and anaphylaxis,20 so the more safe 
sublingual route was developed and validated.21 In recent 
years, the indications, contraindications, and precautions 
for giving SIT have been clearly stated in a World Health 
Organization (WHO) document, where it is emphasized 
that SIT is safe when correctly prescribed and administered, 
and when high-quality allergenic extracts are used.1,22,23 The 
effects of SIT are both curative and preventive. SIT is able 
to reduce symptoms and the need for medications in asthma 
and rhinitis, maintains its clinical efficacy for years after 
discontinuation, prevents onset of new sensitizations, and 
prevents onset of asthma in patients with rhinitis alone.24,25 
Thus, SIT is an allergen-oriented disease-modifying treat-
ment, and has enormous potential for development.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Patient adherence
AR is considered to be a chronic illness, therefore adherence 
to long-term therapy is important. In this regard, WHO defines 
treatment adherence as an individual behavior which consists 
of both compliance (ie, taking the prescribed drugs at the indi-
cated dosage and with the suggested frequency) and persistence 
(ie, continuation of treatment for the recommended duration).26 
A patients is considered “adherent to treatment” if he or she 
takes more than 80% of the prescribed drug. Several factors 
may significantly affect adherence to treatment, positively or 
negatively. Some of these factors depend on the particular 
characteristics of the patient or on their general socioeconomic 
context, whereas others depend on the prescribed drug and the 
schedule. Surveys of patient behavior show that in about 50% 
of cases the drug is not used as prescribed by the doctor.26 The 
most frequent reason given by patients to justify their failed 
adherence is forgetfulness. A possible cause of this phenom-
enon may be the psychologic mechanism of negation, eg, the 
negation of the illness and of factors related to the treatment. 
Other factors involved in impaired adherence may include 
cost, difficulty of use, manageability, tolerability, and safety. 
On the other hand, it has been reported that patients are well 
motivated to adhere to a treatment when they understand and 
accept the diagnosis, agree with the doctor about treatment, 
and are able to discuss their concerns about the treatment with 
the doctor. The WHO document suggests that simplification 
of treatment may be an effective strategy for improving adher-
ence.26 Moreover, pharmaceutical manufacturers may enhance 
adherence by developing drugs which are effective, easy to use, 
and well tolerated. Another important issue is the information 
provided for physicians and patients, as well as reinforcement 
of the therapeutic alliance between all people involved in the 
therapeutic pathway. In this regard, the treatment of AR is 
based on the prescription of antihistamines first-line, mainly 
the second-generation agents.27 In fact, second-generation 
antihistamines are characterized by good efficacy and an 
optimal safety profile. Both doctors and patients maintain 
that effectiveness (including early activity and prolonged 
effect), safety, easy of use, and once-daily administration are 
relevant factors for enhancing treatment adherence. Ebastine 
is a second-generation antihistamine with good efficacy and is 
well tolerated, for which a new formulation has recently been 
devised, ie, a fast-dissolving tablet (FDT), characterized by 
rapid disintegration in the mouth.
Pharmacology of ebastine
Ebastine is a second-generation H1-receptor antagonist with an 
oxypiperidine-based structure, the active form of which is the 
metabolite, carebastine.28 Ebastine is administered orally once 
daily, and is indicated for treatment of symptoms of allergic 
rhinitis and chronic idiopathic urticaria, and in some countries, 
for relief from mosquito bites or atopic dermatitis.
Ebastine is rapidly absorbed after oral administration, 
but undergoes extensive first-pass metabolism to its active 
metabolite.29 Steady-state concentrations are achieved after 
four days of administration, and food intake does not affect 
the pharmacokinetics. Carebastine is mainly excreted in the 
urine. The pharmacokinetics are also unaffected by gender, 
but are affected by age, in that elderly patients show a shorter 
time to peak concentration than younger patients. The pres-
ence of mild to severe renal or hepatic impairment does 
not alter the pharmacokinetics of carebastine to a clinically 
significant extent. There is a drug interaction with ketocon-
azole and erythromycin, in that both drugs increase the peak 
concentration.
With regard to its pharmacodynamic properties, ebastine 
at doses $10 mg significantly reduces the histamine-induced 
cutaneous wheal response. Overall, ebastine 10 mg has been 
shown to be as effective at inhibiting the histamine-induced 
wheal response as several other antihistamines, includ-
ing loratadine, cetirizine, fexofenadine, and mizolastine.30 
Ebastine 10 mg and 30 mg significantly protect against 
histamine-induced bronchoconstriction compared with pla-
cebo in asthmatic patients.
The antiallergic effects of ebastine have been assessed 
by cutaneous and nasal challenge with allergens, and by 
measurement of inflammatory mediators. Ebastine 20 mg 
significantly reduced both wheal and flare responses to aller-
gens. In addition, a single dose of ebastine 10 mg reduced 
the diameter of grass pollen-induced wheal. Ebastine also 
reduced the nasal symptoms occurring after nasal provoca-
tion with grass pollen.
In addition to blocking the H1-receptor, an antihistamine 
may have other effects that contribute to its antiallergic effect. 
Consequently, the effect of ebastine on various mediators 
of inflammation has been investigated. In vitro ebastine 
inhibits anti-IgE-induced release of prostaglandins and 
leukotrienes by nasal polyp cells and cytokines, includ-
ing granulocyte–macrophage colony-stimulating factor 
(GM-CSF), tumor necrosis factor, and IL-8. Ebastine also 
reduces the release of GM-CSF in nasal secretions, nasal 
eosinophilia (assessed using nasal smears), serum eosino-
phil cationic protein levels, and peripheral blood eosinophil 
count.
In conclusion, maximum plasma concentrations are 
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after four days. Ebastine can be administered once daily, with 
or without food. Dose modifications are not needed in elderly 
patients, or in those with renal or mild–moderate hepatic impair-
ment. Coadministration with ketoconazole or erythromycin 
increases plasma levels, but without clinical consequences. 
Ebastine produces a dose-dependent inhibition of the cutaneous 
reaction to histamine, increases the threshold quantity of pollen 
required to induce an allergic reaction in nasal challenge, and 
the antihistaminic effect lasts for more than 48 hours.
Efficacy
The efficacy of once-daily oral ebastine in the management 
of allergic rhinitis has been evaluated in a number of well 
designed clinical trials in adults and adolescents. Most of 
these trials were randomized, double-blind, and placebo- or 
active-controlled. Almost all major studies with the regular for-
mulation of ebastine were performed before the current ARIA 
classification of the intermittent and persistent forms of allergic 
rhinitis. Patients were considered in those studies as suffering 
from seasonal or perennial AR. In addition, patient preference 
trials with the FDT formulation used the ARIA classification. 
In most trials, the evaluation of efficacy was on the basis 
of an assessment of nasal symptoms (rhinorrhea, sneezing, 
itching, and obstruction) and ocular symptoms (itch, tearing, 
hyperemia), using a four-point scale, ie, 0 = absent, 1 = mild, 
2 = moderate, 3 = severe. The studies are very synthetically 
reported, referring to a very recent exhaustive review.30
Seasonal allergic rhinitis
There are eight studies which showed that ebastine was sig-
nificantly more effective than placebo at relieving symptoms 
of seasonal AR.31–38 Overall, most trials reported that doses of 
10 mg and 20 mg once daily were more effective than placebo. 
In terms of the patient’s global evaluation of efficacy, ebastine 
20 mg (but not 10 mg), whether used in the morning or after-
noon, was rated significantly better than placebo. In comparison 
with other second-generation antihistamines, ebastine was as 
effective as cetirizine and at least as effective as loratadine. In 
addition, a meta-analysis reported that ebastine was more effec-
tive than loratadine.39 Interestingly, in one noncomparative study 
specifically evaluating nasal obstruction, ebastine was able to 
reduce this symptom in patients with pollen allergy.40
Perennial allergic rhinitis
Ebastine was significantly more effective than placebo at 
relieving most symptoms of perennial AR, as reported by 
four studies.41–44 Clinical efficacy was evaluated as good or 
very good by most patients.
Persistent allergic rhinitis
Only one study has been performed in patients with persis-
tent allergic rhinitis.40 Treatment with ebastine significantly 
improved nasal symptoms and nasal airflow, as assessed by 
rhinomanometry. In addition, ebastine treatment significantly 
modified the response to the nasal decongestion test.
Safety and tolerability
Ebastine was generally well tolerated in clinical trials involv-
ing patients with allergic rhinitis. The incidence of adverse 
events was similar to that of placebo. Moreover, the active 
comparator trials showed that the incidence of adverse events 
with ebastine was similar to that with loratadine or cetirizine. 
In addition, the severity of these adverse events was mild or 
moderate in most cases.
The most common adverse events, recorded in trials 
concerning more than 3000 patients, were headache (7.9%), 
drowsiness (3%), and dry mouth (2.1%). Two long-term 
studies of three to four months’ duration showed good toler-
ability, with the most common adverse event reported being 
headache.34,35
Regarding cardiac safety, there is a possibility that some 
antihistamines, including terfenadine and astemizole, are 
associated with prolongation of the QTc interval and the con-
sequent possible development of fatal arrhythmias, such as 
torsade de pointes.1 This phenomenon is related to blockade 
of the potassium channels involved in the cardiac repolariza-
tion phase by certain drugs, but not consequent to H1-block. 
Therefore, there is no class effect for antihistamines. The 
ebastine trials showed that doses of 10 mg and 20 mg have 
no clinically relevant effect on the QTc interval.46 In addition, 
there were no problems with possible interaction with other 
drugs, such as erythromycin and ketoconazole.
With regard to central nervous system tolerability, it 
is well known that the second-generation antihistamines 
are generally less sedating than the first-generation ones.47 
A risk:benefit ratio has been calculated on the basis of the 
number of psychomotor and cognitive tests impaired by a 
drug. Ebastine was one of the few antihistamines to produce 
no impairment in any test, and thus has a very favorable 
risk:benefit ratio for sedation.47
In conclusion, ebastine is generally well tolerated. The 
most common adverse events include headache, somnolence, 
and dry mouth. Coadministration with ketoconazole or 
erythromycin is not clinically relevant for cardiac adverse 
events. Ebastine 10 mg and 20 mg are not sedating, and do 
not impair cognitive or psychomotor performance, including 
driving ability.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Ebastine fast-dissolving tablets
The FDT that has been developed is bioequivalent with the 
regular tablet form. This is a unique freeze-dried medicinal 
tablet that disintegrates immediately in the oral cavity. Phar-
macokinetic bioequivalence between ebastine FDT and the 
regular tablet was demonstrated in healthy males, in whom 
the range for equivalence was 0.8–1.25.48 Three preference 
studies have been conducted,49–51 and are discussed in the next 
section. There is only one experimental study conducted so 
far with FDT ebastine.52 It explored the ability of ebastine to 
modulate interferon-gamma in patients with persistent aller-
gic rhinitis. Ebastine FDT dissolves rapidly in the mouth and 
can be taken without the aid of a drink and is bioequivalent 
to the regular ebastine tablet.
Patient-focused perspectives
The new FDT formulation has been developed to improve 
satisfaction and treatment adherence in patients. In this 
regard, three studies have been conducted.
The first study evaluated the preferences of AR patients 
who were given either a placebo version of ebastine FDT 
or a placebo version of the ebastine regular tablet.49 AR 
patients from Germany, Italy, and Mexico, who were 
regular consumers of oral antihistamines, were recruited 
for this randomized crossover study. Patients were inter-
viewed at home by an interviewer using a computer-
assisted telephone interview technique, and the findings 
were analysed using descriptive statistics. A total of 420 
patients participated (140 from each country), 70% with 
intermittent and 24% with persistent AR. Ebastine FDT 
was significantly better than the regular tablet for sensa-
tion of dissolving, taste left in the mouth, initial taste, and 
texture. Overall, 83% of patients preferred ebastine FDT 
to the regular tablet.
The second study evaluated patient perception of the 
onset of action and overall satisfaction with ebastine FDT 
in 100 patients with intermittent and persistent AR.50 This 
was a cross-sectional, multicenter, pharmacy-based survey 
involving adult patients. Via a telephone interview, patients 
were asked to evaluate the characteristics of ebastine FDT 
in comparison with their previous experience of other anti-
histamines. Patients rated ebastine very highly (mean scores 
were 4.5–4.7 out of a possible 5) for onset of action, with 
high statistical significance (P , 0.001). A total of 85% of 
patients perceived the onset of action of ebastine FDT to 
be fast or very fast, and 77% indicated that it acted faster 
than their usual antihistamine. A total of 96% were satisfied 
or very satisfied with ebastine FDT, 98% were interested 
in using the drug again, and FDT was significantly better 
appreciated than the regular tablets (P , 0.001).
The third study assessed patient satisfaction with ebas-
tine FDT using the Treatment Satisfaction Questionnaire 
for Medication.51 This was an international, multicenter, 
observational study involving 461 patients with intermittent 
or persistent AR who had received a prescription for ebastine 
FDT 20 mg in the previous two months. The overall rat-
ings for effectiveness, side effects, convenience, and global 
satisfaction were high for ebastine FDT. A total of 79% of 
patients reported a fast or very fast onset of action. On the 
last day of treatment, patients reported a significant improve-
ment in the intensity and relief of AR symptoms. Ninety-five 
percent of patients reported good or very good tolerability 
with ebastine FDT. Compared with the patient’s experience 
of previous therapy, ebastine FDT was considered better or 
much better for efficacy (81%), tolerability (73%), onset of 
action (79%), and convenience (94%, P , 0.001).
These three studies demonstrate that ebastine FDT is 
associated with a very high satisfaction rate and significant 
relief of AR symptoms, and, consequently, patients reported 
a preference for the FDT formulation over previous antihis-
tamines that they had used.
In conclusion, patients find ebastine FDT convenient and 
easy to use, perceive it to have a rapid onset of action, and 
report high levels of satisfaction with treatment. In addition, 
ebastine FDT may be useful for patients with swallowing 
difficulties, gastrointestinal problems, or a particularly active 
lifestyle.
Conclusion
Histamine plays a significant pathogenic role in AR, thus the use 
of antihistamines is a cornerstone of treatment.53 In this regard, 
second-generation antihistamines should be prescribed as first-
line treatment. Ebastine has a good efficacy and safety profile. In 
addition, the new FDT formulation meets patients’ needs, in that 
it has the same efficacy and safety profile as the regular tablets, 
is easy to use, portable, and is perceived as having a rapid onset 
of action. All these issues improve treatment compliance and 
consequently AR management. Therefore, ebastine FDT should 
be used for its convenience and adherence profile, although it 
should not be used if ineffective in a particular patient. In terms 
of cost, ebastine FDT is approximately the same price as the 
regular tablets, and their cost is comparable with that of other 
antihistamines in the European Community.
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